About
About Cleveland BioLabs Inc
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
Visit company website
5 years, 4 months ago
Cleveland BioLabs, Inc is currently in a long term uptrend where the price is trading 5.3% above its 200 day moving average.
From a valuation standpoint, the stock is 78.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 294.7.
Cleveland BioLabs, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 1.8% to $-695K since the same quarter in the previous year.
Finally, its free cash flow fell by 115.4% to $-788K since the same quarter in the previous year.
Based on the above factors, Cleveland BioLabs, Inc gets an overall score of 3/5.